Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials

J Intern Med. 2000 May;247(5):553-62. doi: 10.1046/j.1365-2796.2000.00631.x.

Abstract

Objective: To assess the length of oral anticoagulant therapy (short versus long duration) after a first episode of venous thromboembolism (VTE).

Design: Meta-analysis of randomized controlled trials, comparing two durations of anticoagulation, identified in 1999 by a computerized search of the Cochrane Controlled Trial Register, Medline and Embase, completed by an extensive review of the references of pertinent articles.

Setting and subjects: The meta-analysis was performed on literature data. Seven published controlled trials were included. Relative risks with 95% confidence intervals were computed using the relative risk logarithm method. Statistical significance was set up at 0.01 for the test of association.

Main outcome measures: Outcomes are major haemorrhage and recurrence after a 12-month follow-up.

Results: For the recurrence end-point (sample size of 2304 patients), a duration treatment of 12-24 weeks seems preferable to a 3-6 week regimen, with a relative risk (RR) of 0.60 (95% CI: 0.45-0.79, P < 0.001). For the major haemorrhage end-point (1823 patients), the RR is not significantly different from 1 (RR = 1.43, 95% CI: 0.51-4.01, P = 0. 5). The results were similar for the subgroup 'permanent risk factors' or 'idiopathic VTE' (RR for recurrence = 0.48, 95% CI: 0. 34-0.68, P < 0.001). The tendency was similar, although not reaching statistical significance, for the 'temporary risk factors' subgroup (RR for recurrence = 0.34, 95% CI: 0.13-0.93, P = 0.035).

Conclusions: After a first episode of VTE, a long-term treatment regimen allows a significant reduction in the incidence of recurrences without increasing the incidence of bleeding events.

Publication types

  • Meta-Analysis

MeSH terms

  • Acute Disease
  • Administration, Oral
  • Anticoagulants / administration & dosage*
  • Heparin / administration & dosage*
  • Humans
  • Pulmonary Embolism / etiology
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Risk Factors
  • Survival Analysis
  • Thromboembolism / complications
  • Thromboembolism / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Heparin